aluates Reports

$ 0.0

Automative

Global Herceptin (Trastuzumab) and Biosimilar Market Research Report 2025

Published Date: May 2025

Report Code: QYRE-Auto-20S14777

Global Herceptin Trastuzumab and Biosimilar Market Research Report 2023

BUY CHAPTERS

Global Herceptin (Trastuzumab) and Biosimilar Market Research Report 2025

Code: QYRE-Auto-20S14777

Report

May 2025

Pages:80

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Roche

Amgen Inc

Organon

TEVA

Viatris

Pfizer Inc

Herceptin (Trastuzumab) and Biosimilar Market Size

The global market for Herceptin (Trastuzumab) and Biosimilar was valued at US$ 4964 million in the year 2024 and is projected to reach a revised size of US$ 6860 million by 2031, growing at a CAGR of 4.8% during the forecast period.

Herceptin (Trastuzumab) and Biosimilar Market

Trastuzumab, sold under the brand name Herceptin among others, is a monoclonal antibody used to treat breast cancer and stomach cancer.

North American market for Herceptin (Trastuzumab) and Biosimilar is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Herceptin (Trastuzumab) and Biosimilar is estimated to increase from $ million in 2024 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Herceptin (Trastuzumab) and Biosimilar include Roche, Amgen, Pfizer, Organon, Teva, Viatris, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Herceptin (Trastuzumab) and Biosimilar, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Herceptin (Trastuzumab) and Biosimilar.

The Herceptin (Trastuzumab) and Biosimilar market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Herceptin (Trastuzumab) and Biosimilar market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Herceptin (Trastuzumab) and Biosimilar manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Herceptin (Trastuzumab) and Biosimilar Market Report

Report Metric	Details
Report Name	Herceptin (Trastuzumab) and Biosimilar Market
Accounted market size in year	US$ 4964 million
Forecasted market size in 2031	US$ 6860 million
CAGR	4.8%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	Brand Biosimilar
Segment by Application	Breast Cancer Stomach Cancer
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Roche, Amgen, Pfizer, Organon, Teva, Viatris
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Herceptin (Trastuzumab) and Biosimilar manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Herceptin (Trastuzumab) and Biosimilar in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

How fast is Herceptin (Trastuzumab) and Biosimilar Market growing?

Ans: The Herceptin (Trastuzumab) and Biosimilar Market witnessing a CAGR of 4.8% during the forecast period 2025-2031.

What is the Herceptin (Trastuzumab) and Biosimilar Market size in 2031?

Ans: The Herceptin (Trastuzumab) and Biosimilar Market size in 2031 will be US$ 6860 million.

Who are the main players in the Herceptin (Trastuzumab) and Biosimilar Market report?

Ans: The main players in the Herceptin (Trastuzumab) and Biosimilar Market are Roche, Amgen, Pfizer, Organon, Teva, Viatris

What are the Application segmentation covered in the Herceptin (Trastuzumab) and Biosimilar Market report?

Ans: The Applications covered in the Herceptin (Trastuzumab) and Biosimilar Market report are Breast Cancer, Stomach Cancer

What are the Type segmentation covered in the Herceptin (Trastuzumab) and Biosimilar Market report?

Ans: The Types covered in the Herceptin (Trastuzumab) and Biosimilar Market report are Brand, Biosimilar

Recommended Reports

Breast Cancer Treatments

Monoclonal Antibody & Biosimilar

Cancer Immunotherapy

1 Herceptin (Trastuzumab) and Biosimilar Market Overview

1.1 Product Definition

1.2 Herceptin (Trastuzumab) and Biosimilar by Type

1.2.1 Global Herceptin (Trastuzumab) and Biosimilar Market Value Comparison by Type (2024 VS 2031)

1.2.2 Brand

1.2.3 Biosimilar

1.3 Herceptin (Trastuzumab) and Biosimilar by Application

1.3.1 Global Herceptin (Trastuzumab) and Biosimilar Market Value by Application (2024 VS 2031)

1.3.2 Breast Cancer

1.3.3 Stomach Cancer

1.4 Global Herceptin (Trastuzumab) and Biosimilar Market Size Estimates and Forecasts

1.4.1 Global Herceptin (Trastuzumab) and Biosimilar Revenue 2020-2031

1.4.2 Global Herceptin (Trastuzumab) and Biosimilar Sales 2020-2031

1.4.3 Global Herceptin (Trastuzumab) and Biosimilar Market Average Price (2020-2031)

1.5 Assumptions and Limitations

2 Herceptin (Trastuzumab) and Biosimilar Market Competition by Manufacturers

2.1 Global Herceptin (Trastuzumab) and Biosimilar Sales Market Share by Manufacturers (2020-2025)

2.2 Global Herceptin (Trastuzumab) and Biosimilar Revenue Market Share by Manufacturers (2020-2025)

2.3 Global Herceptin (Trastuzumab) and Biosimilar Average Price by Manufacturers (2020-2025)

2.4 Global Key Players of Herceptin (Trastuzumab) and Biosimilar, Industry Ranking, 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Herceptin (Trastuzumab) and Biosimilar, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Herceptin (Trastuzumab) and Biosimilar, Product Type & Application

2.7 Global Key Manufacturers of Herceptin (Trastuzumab) and Biosimilar, Date of Enter into This Industry

2.8 Global Herceptin (Trastuzumab) and Biosimilar Market Competitive Situation and Trends

2.8.1 Global Herceptin (Trastuzumab) and Biosimilar Market Concentration Rate

2.8.2 The Global 5 and 10 Largest Herceptin (Trastuzumab) and Biosimilar Players Market Share by Revenue

2.8.3 Global Herceptin (Trastuzumab) and Biosimilar Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global Herceptin (Trastuzumab) and Biosimilar Market Scenario by Region

3.1 Global Herceptin (Trastuzumab) and Biosimilar Market Size by Region: 2020 Versus 2024 Versus 2031

3.2 Global Herceptin (Trastuzumab) and Biosimilar Sales by Region: 2020-2031

3.2.1 Global Herceptin (Trastuzumab) and Biosimilar Sales by Region: 2020-2025

3.2.2 Global Herceptin (Trastuzumab) and Biosimilar Sales by Region: 2026-2031

3.3 Global Herceptin (Trastuzumab) and Biosimilar Revenue by Region: 2020-2031

3.3.1 Global Herceptin (Trastuzumab) and Biosimilar Revenue by Region: 2020-2025

3.3.2 Global Herceptin (Trastuzumab) and Biosimilar Revenue by Region: 2026-2031

3.4 North America Herceptin (Trastuzumab) and Biosimilar Market Facts & Figures by Country

3.4.1 North America Herceptin (Trastuzumab) and Biosimilar Market Size by Country: 2020 VS 2024 VS 2031

3.4.2 North America Herceptin (Trastuzumab) and Biosimilar Sales by Country (2020-2031)

3.4.3 North America Herceptin (Trastuzumab) and Biosimilar Revenue by Country (2020-2031)

3.4.4 United States

3.4.5 Canada

3.5 Europe Herceptin (Trastuzumab) and Biosimilar Market Facts & Figures by Country

3.5.1 Europe Herceptin (Trastuzumab) and Biosimilar Market Size by Country: 2020 VS 2024 VS 2031

3.5.2 Europe Herceptin (Trastuzumab) and Biosimilar Sales by Country (2020-2031)

3.5.3 Europe Herceptin (Trastuzumab) and Biosimilar Revenue by Country (2020-2031)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Herceptin (Trastuzumab) and Biosimilar Market Facts & Figures by Region

3.6.1 Asia Pacific Herceptin (Trastuzumab) and Biosimilar Market Size by Region: 2020 VS 2024 VS 2031

3.6.2 Asia Pacific Herceptin (Trastuzumab) and Biosimilar Sales by Region (2020-2031)

3.6.3 Asia Pacific Herceptin (Trastuzumab) and Biosimilar Revenue by Region (2020-2031)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Southeast Asia

3.7 Latin America Herceptin (Trastuzumab) and Biosimilar Market Facts & Figures by Country

3.7.1 Latin America Herceptin (Trastuzumab) and Biosimilar Market Size by Country: 2020 VS 2024 VS 2031

3.7.2 Latin America Herceptin (Trastuzumab) and Biosimilar Sales by Country (2020-2031)

3.7.3 Latin America Herceptin (Trastuzumab) and Biosimilar Revenue by Country (2020-2031)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Herceptin (Trastuzumab) and Biosimilar Market Facts & Figures by Country

3.8.1 Middle East and Africa Herceptin (Trastuzumab) and Biosimilar Market Size by Country: 2020 VS 2024 VS 2031

3.8.2 Middle East and Africa Herceptin (Trastuzumab) and Biosimilar Sales by Country (2020-2031)

3.8.3 Middle East and Africa Herceptin (Trastuzumab) and Biosimilar Revenue by Country (2020-2031)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global Herceptin (Trastuzumab) and Biosimilar Sales by Type (2020-2031)

4.1.1 Global Herceptin (Trastuzumab) and Biosimilar Sales by Type (2020-2025)

4.1.2 Global Herceptin (Trastuzumab) and Biosimilar Sales by Type (2026-2031)

4.1.3 Global Herceptin (Trastuzumab) and Biosimilar Sales Market Share by Type (2020-2031)

4.2 Global Herceptin (Trastuzumab) and Biosimilar Revenue by Type (2020-2031)

4.2.1 Global Herceptin (Trastuzumab) and Biosimilar Revenue by Type (2020-2025)

4.2.2 Global Herceptin (Trastuzumab) and Biosimilar Revenue by Type (2026-2031)

4.2.3 Global Herceptin (Trastuzumab) and Biosimilar Revenue Market Share by Type (2020-2031)

4.3 Global Herceptin (Trastuzumab) and Biosimilar Price by Type (2020-2031)

5 Segment by Application

5.1 Global Herceptin (Trastuzumab) and Biosimilar Sales by Application (2020-2031)

5.1.1 Global Herceptin (Trastuzumab) and Biosimilar Sales by Application (2020-2025)

5.1.2 Global Herceptin (Trastuzumab) and Biosimilar Sales by Application (2026-2031)

5.1.3 Global Herceptin (Trastuzumab) and Biosimilar Sales Market Share by Application (2020-2031)

5.2 Global Herceptin (Trastuzumab) and Biosimilar Revenue by Application (2020-2031)

5.2.1 Global Herceptin (Trastuzumab) and Biosimilar Revenue by Application (2020-2025)

5.2.2 Global Herceptin (Trastuzumab) and Biosimilar Revenue by Application (2026-2031)

5.2.3 Global Herceptin (Trastuzumab) and Biosimilar Revenue Market Share by Application (2020-2031)

5.3 Global Herceptin (Trastuzumab) and Biosimilar Price by Application (2020-2031)

6 Key Companies Profiled

6.1 Roche

6.1.1 Roche Company Information

6.1.2 Roche Description and Business Overview

6.1.3 Roche Herceptin (Trastuzumab) and Biosimilar Sales, Revenue and Gross Margin (2020-2025)

6.1.4 Roche Herceptin (Trastuzumab) and Biosimilar Product Portfolio

6.1.5 Roche Recent Developments/Updates

6.2 Amgen

6.2.1 Amgen Company Information

6.2.2 Amgen Description and Business Overview

6.2.3 Amgen Herceptin (Trastuzumab) and Biosimilar Sales, Revenue and Gross Margin (2020-2025)

6.2.4 Amgen Herceptin (Trastuzumab) and Biosimilar Product Portfolio

6.2.5 Amgen Recent Developments/Updates

6.3 Pfizer

6.3.1 Pfizer Company Information

6.3.2 Pfizer Description and Business Overview

6.3.3 Pfizer Herceptin (Trastuzumab) and Biosimilar Sales, Revenue and Gross Margin (2020-2025)

6.3.4 Pfizer Herceptin (Trastuzumab) and Biosimilar Product Portfolio

6.3.5 Pfizer Recent Developments/Updates

6.4 Organon

6.4.1 Organon Company Information

6.4.2 Organon Description and Business Overview

6.4.3 Organon Herceptin (Trastuzumab) and Biosimilar Sales, Revenue and Gross Margin (2020-2025)

6.4.4 Organon Herceptin (Trastuzumab) and Biosimilar Product Portfolio

6.4.5 Organon Recent Developments/Updates

6.5 Teva

6.5.1 Teva Company Information

6.5.2 Teva Description and Business Overview

6.5.3 Teva Herceptin (Trastuzumab) and Biosimilar Sales, Revenue and Gross Margin (2020-2025)

6.5.4 Teva Herceptin (Trastuzumab) and Biosimilar Product Portfolio

6.5.5 Teva Recent Developments/Updates

6.6 Viatris

6.6.1 Viatris Company Information

6.6.2 Viatris Description and Business Overview

6.6.3 Viatris Herceptin (Trastuzumab) and Biosimilar Sales, Revenue and Gross Margin (2020-2025)

6.6.4 Viatris Herceptin (Trastuzumab) and Biosimilar Product Portfolio

6.6.5 Viatris Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Herceptin (Trastuzumab) and Biosimilar Industry Chain Analysis

7.2 Herceptin (Trastuzumab) and Biosimilar Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Herceptin (Trastuzumab) and Biosimilar Production Mode & Process Analysis

7.4 Herceptin (Trastuzumab) and Biosimilar Sales and Marketing

7.4.1 Herceptin (Trastuzumab) and Biosimilar Sales Channels

7.4.2 Herceptin (Trastuzumab) and Biosimilar Distributors

7.5 Herceptin (Trastuzumab) and Biosimilar Customer Analysis

8 Herceptin (Trastuzumab) and Biosimilar Market Dynamics

8.1 Herceptin (Trastuzumab) and Biosimilar Industry Trends

8.2 Herceptin (Trastuzumab) and Biosimilar Market Drivers

8.3 Herceptin (Trastuzumab) and Biosimilar Market Challenges

8.4 Herceptin (Trastuzumab) and Biosimilar Market Restraints

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Roche

Amgen Inc

Organon

TEVA

Viatris

Pfizer Inc

List of Tables

Table 1. Global Herceptin (Trastuzumab) and Biosimilar Market Value Comparison by Type (2024 VS 2031) & (US$ Million)

Table 2. Global Herceptin (Trastuzumab) and Biosimilar Market Value by Application (2024 VS 2031) & (US$ Million)

Table 3. Global Herceptin (Trastuzumab) and Biosimilar Market Competitive Situation by Manufacturers in 2024

Table 4. Global Herceptin (Trastuzumab) and Biosimilar Sales (K Units) of Key Manufacturers (2020-2025)

Table 5. Global Herceptin (Trastuzumab) and Biosimilar Sales Market Share by Manufacturers (2020-2025)

Table 6. Global Herceptin (Trastuzumab) and Biosimilar Revenue (US$ Million) by Manufacturers (2020-2025)

Table 7. Global Herceptin (Trastuzumab) and Biosimilar Revenue Share by Manufacturers (2020-2025)

Table 8. Global Market Herceptin (Trastuzumab) and Biosimilar Average Price (US$/Unit) of Key Manufacturers (2020-2025)

Table 9. Global Key Players of Herceptin (Trastuzumab) and Biosimilar, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Herceptin (Trastuzumab) and Biosimilar, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Herceptin (Trastuzumab) and Biosimilar, Product Type & Application

Table 12. Global Key Manufacturers of Herceptin (Trastuzumab) and Biosimilar, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Herceptin (Trastuzumab) and Biosimilar by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Herceptin (Trastuzumab) and Biosimilar as of 2024)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Herceptin (Trastuzumab) and Biosimilar Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 17. Global Herceptin (Trastuzumab) and Biosimilar Sales by Region (2020-2025) & (K Units)

Table 18. Global Herceptin (Trastuzumab) and Biosimilar Sales Market Share by Region (2020-2025)

Table 19. Global Herceptin (Trastuzumab) and Biosimilar Sales by Region (2026-2031) & (K Units)

Table 20. Global Herceptin (Trastuzumab) and Biosimilar Sales Market Share by Region (2026-2031)

Table 21. Global Herceptin (Trastuzumab) and Biosimilar Revenue by Region (2020-2025) & (US$ Million)

Table 22. Global Herceptin (Trastuzumab) and Biosimilar Revenue Market Share by Region (2020-2025)

Table 23. Global Herceptin (Trastuzumab) and Biosimilar Revenue by Region (2026-2031) & (US$ Million)

Table 24. Global Herceptin (Trastuzumab) and Biosimilar Revenue Market Share by Region (2026-2031)

Table 25. North America Herceptin (Trastuzumab) and Biosimilar Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 26. North America Herceptin (Trastuzumab) and Biosimilar Sales by Country (2020-2025) & (K Units)

Table 27. North America Herceptin (Trastuzumab) and Biosimilar Sales by Country (2026-2031) & (K Units)

Table 28. North America Herceptin (Trastuzumab) and Biosimilar Revenue by Country (2020-2025) & (US$ Million)

Table 29. North America Herceptin (Trastuzumab) and Biosimilar Revenue by Country (2026-2031) & (US$ Million)

Table 30. Europe Herceptin (Trastuzumab) and Biosimilar Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 31. Europe Herceptin (Trastuzumab) and Biosimilar Sales by Country (2020-2025) & (K Units)

Table 32. Europe Herceptin (Trastuzumab) and Biosimilar Sales by Country (2026-2031) & (K Units)

Table 33. Europe Herceptin (Trastuzumab) and Biosimilar Revenue by Country (2020-2025) & (US$ Million)

Table 34. Europe Herceptin (Trastuzumab) and Biosimilar Revenue by Country (2026-2031) & (US$ Million)

Table 35. Asia Pacific Herceptin (Trastuzumab) and Biosimilar Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 36. Asia Pacific Herceptin (Trastuzumab) and Biosimilar Sales by Region (2020-2025) & (K Units)

Table 37. Asia Pacific Herceptin (Trastuzumab) and Biosimilar Sales by Region (2026-2031) & (K Units)

Table 38. Asia Pacific Herceptin (Trastuzumab) and Biosimilar Revenue by Region (2020-2025) & (US$ Million)

Table 39. Asia Pacific Herceptin (Trastuzumab) and Biosimilar Revenue by Region (2026-2031) & (US$ Million)

Table 40. Latin America Herceptin (Trastuzumab) and Biosimilar Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 41. Latin America Herceptin (Trastuzumab) and Biosimilar Sales by Country (2020-2025) & (K Units)

Table 42. Latin America Herceptin (Trastuzumab) and Biosimilar Sales by Country (2026-2031) & (K Units)

Table 43. Latin America Herceptin (Trastuzumab) and Biosimilar Revenue by Country (2020-2025) & (US$ Million)

Table 44. Latin America Herceptin (Trastuzumab) and Biosimilar Revenue by Country (2026-2031) & (US$ Million)

Table 45. Middle East and Africa Herceptin (Trastuzumab) and Biosimilar Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 46. Middle East and Africa Herceptin (Trastuzumab) and Biosimilar Sales by Country (2020-2025) & (K Units)

Table 47. Middle East and Africa Herceptin (Trastuzumab) and Biosimilar Sales by Country (2026-2031) & (K Units)

Table 48. Middle East and Africa Herceptin (Trastuzumab) and Biosimilar Revenue by Country (2020-2025) & (US$ Million)

Table 49. Middle East and Africa Herceptin (Trastuzumab) and Biosimilar Revenue by Country (2026-2031) & (US$ Million)

Table 50. Global Herceptin (Trastuzumab) and Biosimilar Sales (K Units) by Type (2020-2025)

Table 51. Global Herceptin (Trastuzumab) and Biosimilar Sales (K Units) by Type (2026-2031)

Table 52. Global Herceptin (Trastuzumab) and Biosimilar Sales Market Share by Type (2020-2025)

Table 53. Global Herceptin (Trastuzumab) and Biosimilar Sales Market Share by Type (2026-2031)

Table 54. Global Herceptin (Trastuzumab) and Biosimilar Revenue (US$ Million) by Type (2020-2025)

Table 55. Global Herceptin (Trastuzumab) and Biosimilar Revenue (US$ Million) by Type (2026-2031)

Table 56. Global Herceptin (Trastuzumab) and Biosimilar Revenue Market Share by Type (2020-2025)

Table 57. Global Herceptin (Trastuzumab) and Biosimilar Revenue Market Share by Type (2026-2031)

Table 58. Global Herceptin (Trastuzumab) and Biosimilar Price (US$/Unit) by Type (2020-2025)

Table 59. Global Herceptin (Trastuzumab) and Biosimilar Price (US$/Unit) by Type (2026-2031)

Table 60. Global Herceptin (Trastuzumab) and Biosimilar Sales (K Units) by Application (2020-2025)

Table 61. Global Herceptin (Trastuzumab) and Biosimilar Sales (K Units) by Application (2026-2031)

Table 62. Global Herceptin (Trastuzumab) and Biosimilar Sales Market Share by Application (2020-2025)

Table 63. Global Herceptin (Trastuzumab) and Biosimilar Sales Market Share by Application (2026-2031)

Table 64. Global Herceptin (Trastuzumab) and Biosimilar Revenue (US$ Million) by Application (2020-2025)

Table 65. Global Herceptin (Trastuzumab) and Biosimilar Revenue (US$ Million) by Application (2026-2031)

Table 66. Global Herceptin (Trastuzumab) and Biosimilar Revenue Market Share by Application (2020-2025)

Table 67. Global Herceptin (Trastuzumab) and Biosimilar Revenue Market Share by Application (2026-2031)

Table 68. Global Herceptin (Trastuzumab) and Biosimilar Price (US$/Unit) by Application (2020-2025)

Table 69. Global Herceptin (Trastuzumab) and Biosimilar Price (US$/Unit) by Application (2026-2031)

Table 70. Roche Company Information

Table 71. Roche Description and Business Overview

Table 72. Roche Herceptin (Trastuzumab) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 73. Roche Herceptin (Trastuzumab) and Biosimilar Product

Table 74. Roche Recent Developments/Updates

Table 75. Amgen Company Information

Table 76. Amgen Description and Business Overview

Table 77. Amgen Herceptin (Trastuzumab) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 78. Amgen Herceptin (Trastuzumab) and Biosimilar Product

Table 79. Amgen Recent Developments/Updates

Table 80. Pfizer Company Information

Table 81. Pfizer Description and Business Overview

Table 82. Pfizer Herceptin (Trastuzumab) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 83. Pfizer Herceptin (Trastuzumab) and Biosimilar Product

Table 84. Pfizer Recent Developments/Updates

Table 85. Organon Company Information

Table 86. Organon Description and Business Overview

Table 87. Organon Herceptin (Trastuzumab) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 88. Organon Herceptin (Trastuzumab) and Biosimilar Product

Table 89. Organon Recent Developments/Updates

Table 90. Teva Company Information

Table 91. Teva Description and Business Overview

Table 92. Teva Herceptin (Trastuzumab) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 93. Teva Herceptin (Trastuzumab) and Biosimilar Product

Table 94. Teva Recent Developments/Updates

Table 95. Viatris Company Information

Table 96. Viatris Description and Business Overview

Table 97. Viatris Herceptin (Trastuzumab) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)

Table 98. Viatris Herceptin (Trastuzumab) and Biosimilar Product

Table 99. Viatris Recent Developments/Updates

Table 100. Key Raw Materials Lists

Table 101. Raw Materials Key Suppliers Lists

Table 102. Herceptin (Trastuzumab) and Biosimilar Distributors List

Table 103. Herceptin (Trastuzumab) and Biosimilar Customers List

Table 104. Herceptin (Trastuzumab) and Biosimilar Market Trends

Table 105. Herceptin (Trastuzumab) and Biosimilar Market Drivers

Table 106. Herceptin (Trastuzumab) and Biosimilar Market Challenges

Table 107. Herceptin (Trastuzumab) and Biosimilar Market Restraints

Table 108. Research Programs/Design for This Report

Table 109. Key Data Information from Secondary Sources

Table 110. Key Data Information from Primary Sources

Table 111. Authors List of This Report

List of Figures

Figure 1. Product Picture of Herceptin (Trastuzumab) and Biosimilar

Figure 2. Global Herceptin (Trastuzumab) and Biosimilar Market Value Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Herceptin (Trastuzumab) and Biosimilar Market Share by Type: 2024 & 2031

Figure 4. Brand Product Picture

Figure 5. Biosimilar Product Picture

Figure 6. Global Herceptin (Trastuzumab) and Biosimilar Market Value by Application (2020-2031) & (US$ Million)

Figure 7. Global Herceptin (Trastuzumab) and Biosimilar Market Share by Application: 2024 & 2031

Figure 8. Breast Cancer

Figure 9. Stomach Cancer

Figure 10. Global Herceptin (Trastuzumab) and Biosimilar Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 11. Global Herceptin (Trastuzumab) and Biosimilar Market Size (2020-2031) & (US$ Million)

Figure 12. Global Herceptin (Trastuzumab) and Biosimilar Sales (2020-2031) & (K Units)

Figure 13. Global Herceptin (Trastuzumab) and Biosimilar Average Price (US$/Unit) & (2020-2031)

Figure 14. Herceptin (Trastuzumab) and Biosimilar Report Years Considered

Figure 15. Herceptin (Trastuzumab) and Biosimilar Sales Share by Manufacturers in 2024

Figure 16. Global Herceptin (Trastuzumab) and Biosimilar Revenue Share by Manufacturers in 2024

Figure 17. Global 5 and 10 Largest Herceptin (Trastuzumab) and Biosimilar Players: Market Share by Revenue in Herceptin (Trastuzumab) and Biosimilar in 2024

Figure 18. Herceptin (Trastuzumab) and Biosimilar Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024

Figure 19. Global Herceptin (Trastuzumab) and Biosimilar Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Figure 20. North America Herceptin (Trastuzumab) and Biosimilar Sales Market Share by Country (2020-2031)

Figure 21. North America Herceptin (Trastuzumab) and Biosimilar Revenue Market Share by Country (2020-2031)

Figure 22. United States Herceptin (Trastuzumab) and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 23. Canada Herceptin (Trastuzumab) and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 24. Europe Herceptin (Trastuzumab) and Biosimilar Sales Market Share by Country (2020-2031)

Figure 25. Europe Herceptin (Trastuzumab) and Biosimilar Revenue Market Share by Country (2020-2031)

Figure 26. Germany Herceptin (Trastuzumab) and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 27. France Herceptin (Trastuzumab) and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 28. U.K. Herceptin (Trastuzumab) and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 29. Italy Herceptin (Trastuzumab) and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 30. Russia Herceptin (Trastuzumab) and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 31. Asia Pacific Herceptin (Trastuzumab) and Biosimilar Sales Market Share by Region (2020-2031)

Figure 32. Asia Pacific Herceptin (Trastuzumab) and Biosimilar Revenue Market Share by Region (2020-2031)

Figure 33. China Herceptin (Trastuzumab) and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 34. Japan Herceptin (Trastuzumab) and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 35. South Korea Herceptin (Trastuzumab) and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 36. India Herceptin (Trastuzumab) and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 37. Australia Herceptin (Trastuzumab) and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 38. China Taiwan Herceptin (Trastuzumab) and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 39. Southeast Asia Herceptin (Trastuzumab) and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 40. Latin America Herceptin (Trastuzumab) and Biosimilar Sales Market Share by Country (2020-2031)

Figure 41. Latin America Herceptin (Trastuzumab) and Biosimilar Revenue Market Share by Country (2020-2031)

Figure 42. Mexico Herceptin (Trastuzumab) and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 43. Brazil Herceptin (Trastuzumab) and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 44. Argentina Herceptin (Trastuzumab) and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 45. Middle East and Africa Herceptin (Trastuzumab) and Biosimilar Sales Market Share by Country (2020-2031)

Figure 46. Middle East and Africa Herceptin (Trastuzumab) and Biosimilar Revenue Market Share by Country (2020-2031)

Figure 47. Turkey Herceptin (Trastuzumab) and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 48. Saudi Arabia Herceptin (Trastuzumab) and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 49. UAE Herceptin (Trastuzumab) and Biosimilar Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 50. Global Sales Market Share of Herceptin (Trastuzumab) and Biosimilar by Type (2020-2031)

Figure 51. Global Revenue Market Share of Herceptin (Trastuzumab) and Biosimilar by Type (2020-2031)

Figure 52. Global Herceptin (Trastuzumab) and Biosimilar Price (US$/Unit) by Type (2020-2031)

Figure 53. Global Sales Market Share of Herceptin (Trastuzumab) and Biosimilar by Application (2020-2031)

Figure 54. Global Revenue Market Share of Herceptin (Trastuzumab) and Biosimilar by Application (2020-2031)

Figure 55. Global Herceptin (Trastuzumab) and Biosimilar Price (US$/Unit) by Application (2020-2031)

Figure 56. Herceptin (Trastuzumab) and Biosimilar Value Chain

Figure 57. Channels of Distribution (Direct Vs Distribution)

Figure 58. Bottom-up and Top-down Approaches for This Report

Figure 59. Data Triangulation

Figure 60. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Herceptin Biosimilar Market Insights Forecast to 2030

Global Herceptin Trastuzumab Market Research Report 2024

Trastuzumab Injection Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global HER2 Antibody Market Research Report 2025

Trastuzumab Biosimilar Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Adalimumab Monoclonal Antibody Biosimilar Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Rituximab Biosimilars Market Research Report 2025

Bevacizumab Monoclonal Antibody Biosimilar Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Adalimumab Humira and Biosimilar Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Mono Antibody mAb for HER2 Positive Advanced Breast Cancer Market Research Report 2024

Global Monoclonal Antibody Drugs for Cancer Market Research Report 2024

Rituximab Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Monoclonal antibodies mAbs Biosimilars Market Research Report 2024

Global Anti HER2 Therapy Market Research Report 2025

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions